Microchip Imaging Cytometry Makes Laboratory Testing More Economical, Easy-to-Use and Accessible
|
By LabMedica International staff writers Posted on 25 Aug 2022 |

The economic globalization and the aging population of many countries in the world generate an enormous need for rapid and cost-effective point-of-need laboratory tests. Over the past two years, the entire world has been tackling challenges from COVID-19 pandemic. The general population in many countries are routinely taking nucleic acid tests and/or rapid antigen tests for screening purposes. Healthcare workers are in need of more economical, and easy-to-use diagnostic testing tools to support their healthcare practice. Public health agencies also need powerful diagnostic tools to help them make critical policy decisions. In a typical clinic appointment, laboratory tests go through procedures such as lab requisition, sample collection, sample processing, and reporting. The average turn-around-time may vary from several hours to several days. For many disease diagnoses and monitoring requiring instant information and rapid decision-making, the traditional technology and workflow could not effectively meet the clinical needs.
Meanwhile, there is the “rapid test strip” option such as the COVID antigen test strip and the hCG pregnancy test strip that provides instant test results. These rapid test strips become an important diagnostic tool for screening and monitoring, although the application of the test strips is usually restricted to qualitative tests. Additionally, because of their relatively lower analytical sensitivity, these rapid test strips could not detect biomarkers that have a low quantity in the specimen. Therefore, there is a growing need to develop a quantitative, easy-to-use, and accessible diagnostic instrument and reagents. Given the emerging healthcare needs, scientists and engineers continuously come up with creative diagnostic solutions using a variety of technological approaches. Among these technologies, microfluidics becomes a highly valuable approach to potentially address many of the requirements. Microchip imaging cytometry (MIC) based on microfluidic technologies is such an innovative analytical platform that may change the landscape of the clinical lab testing field.
A team of researchers at the University of Toronto (Toronto, ON, Canada) have published a paper in Opto-Electronic Advances (OEA) that addresses scientific and technical advances in the field of MIC and shows the applications of MIC that may bring more economical, easy-to-use, and accessible healthcare to the public. MIC is a platform technology that can rapidly detect and analyze human biochemical substances such as cells, proteins, and nucleic acids. MIC devices have the attributes of portability, cost-effectiveness, and adaptability while providing quantitative measurements to meet the needs of laboratory testing in a variety of healthcare settings. Based on the use of microfluidic chips, MIC requires less sample and may complete sample preparation automatically. Therefore, they can provide quantitative testing results simply using a finger prick specimen. The decreased reagent consumption and reduced form factor also help improve the accessibility and affordability of healthcare services in remote and resource-limited settings.
The article reviews notable clinical applications of MIC technologies, such as HIV-patient monitoring, sickle disease screening, infectious disease diagnosis, etc. Depending on the level of automation and image capturing formats, MIC devices were classified into three approaches: Static-chip-static-fluid (SCSF), Static-chip-moving-fluid (SCMF) and Moving-chip-static-fluid (MCSF). Brightfield imaging, fluorescence imaging, and lens-free imaging techniques have been adopted in MIC systems. Image acquisition techniques such as time delay integration and temporally coded excitation were demonstrated to achieve higher sensitivity in detecting fast-moving objects in low light levels.
Compared with traditional flow cytometers, MIC analyzes objects such as cells and particles through a relatively wide and shallow microfluidic chip channel. As a result of the breakthrough development of semiconductor sensor devices and information technology in recent years, the light source and imaging detection components of MIC can also achieve higher optoelectronic performance. Thanks to the innovation and development of biotechnology, micro-nano manufacturing, semiconductor materials, information technology, and other fields, MIC will find more important clinical test applications in the future, and promote the development of more economical, easy-to-use, and accessible point-of-need tests. Recent advances in photonics, integrated optics, and imaging technologies promise to increase the sensitivity and functionality of MIC systems while decreasing their size and cost. Colors can be differentiated directly on the silicon CMOS image sensors using several techniques. Progress towards higher sensitivity detectors has also been made by integrating single-photon avalanche diodes in standard CMOS with microfluidic systems.
The development of MIC devices should focus on the following aspects: 1) the device should be portable to fit the diagnostic purpose in varying healthcare scenarios, 2) the device should be easy to use and provide sample-to-answer results rapidly (e.g. 15 minutes), 3) the microfluidic assembly should contain pre-loaded reagents and be disposable. Additionally, the analytical performance of MIC devices, such as sensitivity, accuracy, precision, robustness, needs to meet the certain testing requirements. In the process of instrument and reagent design and development, all these aspects need to be considered. Therefore, engineering design and development need to find the sophisticated balance between complexity, performance and cost, to meet the needs in healthcare and to benefit more patients.
Latest Industry News
- Myriad Genetics to Sell Prenatal Testing Portfolio to Labcorp
- Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition
- Labcorp Acquisition to Strengthen Specialty Testing and Prostate Cancer Assessment
- Collaboration Advances Genomic Instability Biomarker for Prostate Cancer
- Managed Care Report Examines Barriers to Breast Cancer Biomarker Testing
- Expanding Screening and Biomarker Testing Drive Cancer Diagnostics Market Growth
- Expanded Partnership Scales AI-Powered Digital Pathology for Oncology
- Hospital Partnership Advances Clinical Validation of Portable Diagnostic Technology
- Diazyme Expands Chemistry Testing Portfolio With Alfa Wassermann Acquisition
- Global TB Summit Connects Diagnostic Testing With Prevention and Clinical Care
- Agilent's Acquisition of Proscia to Advance AI-Enabled Digital Pathology Workflows
- Digital Pathology Collaboration Expands Laboratory Access to AI-Driven Diagnostics
- Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation
- European Approval Expands Liquid Biopsy Use in Advanced Breast Cancer Testing
- Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China
- Collaboration Advances Automated Benchtop Platform for Routine Blood Testing
Channels
Clinical Chemistry
view channel
Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment
Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more
Multimodal Platform to Combine Blood and Imaging Biomarkers for Lung Nodule Assessment
Lung nodules are commonly detected during chest imaging and require careful risk assessment to determine whether follow-up imaging, additional testing, or biopsy is needed. With millions of patients evaluated... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more
GeneDx Presents Evidence for Wider Clinical Use of Genomic Sequencing at ASHG 2026
GeneDx (Gaithersburg, MD, USA) is presenting 27 scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, taking place October 20–24 in Montreal, Canada.... Read moreHematology
view channel
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read more
Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
Severe blood loss and inadequate tissue oxygenation are leading causes of preventable death after traumatic injury. Blood products are essential in trauma care, but cold-chain storage, short shelf life,... Read moreImmunology
view channel
Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more
Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more
Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more
Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read moreMicrobiology
view channel
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read more
Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
Sepsis and severe infections are difficult to treat because patients with similar clinical presentations may have very different underlying immune responses. Corticosteroids are commonly used in severe... Read morePathology
view channel
AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more
Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
Barrett’s esophagus is a precancerous condition associated with increased risk of esophageal adenocarcinoma. Routine endoscopic biopsy findings guide surveillance and therapy, but histopathology may not... Read moreIndustry
view channel
Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition
Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more







